Korsana Biosciences, Inc. (KRSA) Cash Flow Statement
Where KRSA’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$3.3M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$3.3M −159.8% margin
- Returned to shareholders
- $130,000
- Change in cash
- $8,000 cash at year-end $3.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
KRSA operating cash flow, capex and free cash flow
KRSA cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$49.9M2016 | −$3.3M2025 | — | |
| Capital expenditures | $1.4M2016 | $02025 | −100.0% | |
| Free cash flow | −$51.3M2016 | −$3.3M2025 | — | |
| Free cash flow margin | −2,420.7%2019 | −159.8%2025 | +2,261.0 pts | |
| Stock-based compensation | $9.5M2017 | $441,0002025 | −31.9%/yr | |
| Capex / revenue | 152.8%2019 | 0.0%2025 | −152.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KRSA cash flow by activity
KRSA net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
KRSA cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$3.5M | −$3.1M | −$12.6M | −$18.2M | −$51.6M | −$77.8M | −$123.0M | −$115.3M | −$93.9M | −$63.6M |
| Depreciation & amortization | — | — | $65,000 | $65,000 | $472,000 | $2.3M | $2.7M | $1.5M | $1.7M | $2.2M |
| Stock-based compensation | $441,000 | $625,000 | — | — | $9.6M | $15.0M | $19.6M | $12.4M | $9.5M | — |
| Change in working capital | −$227,000 | −$1.5M | −$4.6M | −$2.9M | $1.4M | −$7.6M | −$2.3M | $3.8M | $1.5M | $4.3M |
| Other non-cash items | $0 | −$363,000 | −$4.1M | −$19.6M | $3.6M | −$4.4M | $751,000 | $0 | $0 | $7.2M |
| Cash from operating activities | −$3.3M | −$4.3M | −$21.2M | −$40.6M | −$36.5M | −$72.5M | −$102.2M | −$97.5M | −$81.2M | −$49.9M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | −$7,000 | −$1.5M | −$6.9M | −$3.4M | −$1.4M | −$1.4M |
| Acquisitions & other investing | — | — | $10.4M | — | $1.5M | $1.5M | $173,000 | $0 | $0 | $0 |
| Cash from investing activities | — | — | $10.4M | — | $1.5M | $18,000 | −$6.7M | −$3.4M | −$1.4M | −$1.4M |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | −$130,000 | — | — | — | — | — | — | — | — | — |
| Shares issued | $165.6M | $10.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$162.1M | $100,000 | $5.0M | $29,000 | $30.8M | $28.1M | $211.6M | $100.9M | $82.6M | $51.3M |
| Cash from financing activities | $3.3M | $10.1M | $5.0M | $29,000 | $30.8M | $28.1M | $211.6M | $100.9M | $82.6M | $51.3M |
| Summary | ||||||||||
| Net change in cash | $8,000 | −$4.3M | −$5.8M | −$40.6M | −$4.3M | −$44.4M | $102.6M | — | — | — |
| Cash at end of period | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $58.2M | $102.6M | — | — | — |
| Free cash flow | −$3.3M | −$4.3M | −$21.2M | −$40.6M | −$36.5M | −$74.0M | −$109.1M | −$100.9M | −$82.6M | −$51.3M |
| Free cash flow margin | −159.8% | −216.7% | — | −13,673.7% | −1,100.1% | −3,223.6% | −2,420.7% | — | — | — |
| Capex / revenue | 0.0% | 0.0% | — | 0.0% | 0.2% | 66.4% | 152.8% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$1.8M | −$3.2M | −$799,000 | −$976,000 | −$324,000 | −$1.4M | $530,000 | −$723,000 | −$1.3M | −$1.5M | −$1.7M | $7.6M |
| Stock-based compensation | $109,000 | — | — | $118,000 | $114,000 | $114,000 | $122,000 | $138,000 | $184,000 | $181,000 | $103,000 | $159,000 |
| Change in working capital | $272,000 | $1.9M | −$875,000 | $594,000 | −$293,000 | $347,000 | −$292,000 | −$768,000 | $32,000 | −$510,000 | $50,000 | −$2.2M |
| Other non-cash items | −$58,000 | $58,000 | $95,000 | $0 | $0 | $0 | $0 | −$363,000 | $0 | $0 | $0 | −$12.4M |
| Cash from operating activities | −$1.4M | −$1.2M | −$1.6M | −$264,000 | −$503,000 | −$968,000 | $360,000 | −$1.7M | −$1.1M | −$1.9M | −$1.5M | −$6.9M |
| Investing activities | ||||||||||||
| Capital expenditures | −$66,000 | −$66,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | — | $0 | — | — | — | — | — | — | — | — | — | $10.4M |
| Cash from investing activities | — | −$66,000 | — | — | — | — | — | — | — | — | — | $10.4M |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | — | $825,000 | $251,000 | $1.8M | −$130,000 | $1.4M | — | — | — | — | — | — |
| Cash from financing activities | — | $825,000 | $251,000 | $1.8M | −$130,000 | $1.4M | — | — | — | — | — | — |
| Summary | ||||||||||||
| Net change in cash | −$1.4M | −$417,000 | −$1.3M | $1.6M | −$633,000 | $407,000 | $360,000 | −$1.7M | −$1.1M | −$1.9M | −$1.5M | $3.5M |
| Cash at end of period | $1.4M | $2.8M | $3.2M | $4.6M | $3.0M | $3.6M | $3.2M | $2.9M | $4.6M | $5.7M | $7.6M | $9.1M |
| Free cash flow | −$1.4M | −$1.2M | −$1.6M | −$264,000 | −$503,000 | −$968,000 | $360,000 | −$1.7M | −$1.1M | −$1.9M | −$1.5M | −$6.9M |
| Free cash flow margin | — | — | −154.0% | −30.2% | −540.9% | −1,195.1% | 19.9% | −884.5% | — | — | — | — |
| Capex / revenue | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | — | — | 0.68 | — | — | — | — | −0.92 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
KRSA cash generation
In fiscal 2025 (ended December 31, 2025), Korsana Biosciences generated -$3.3 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$3.3 million, −159.8% of revenue. It returned $0.1 million to shareholders through dividends ($0) and net share buybacks ($0.1 million). Cash and equivalents rose by $0.0 million over the year.
Related: KRSA income statement, KRSA balance sheet. See the KRSA stock overview for the latest quote and news.
KRSA cash flow FAQ
What is Korsana Biosciences's free cash flow?
Korsana Biosciences's free cash flow was -$3.3 million in fiscal 2025: -$3.3 million of operating cash flow minus $0 of capital expenditures It was -$4.3 million a year earlier..
How much cash does Korsana Biosciences generate from operations?
Korsana Biosciences generated -$3.3 million of cash from operating activities in fiscal 2025.
How much stock does Korsana Biosciences buy back?
Korsana Biosciences spent $0.1 million on net share repurchases in fiscal 2025.